The date for the generics and biosimilars specialist Sandoz to spin out from its parent company Novartis (NOVN: VX) has been announced.
All 100% of the business will go its own way - and trading of new Sandoz Group shares and American Depositary Receipts (ADRs) will begin - on October 4.
This follows Novartis shareholders giving their approval for the spin-off of Sandoz, at an extraordinary general meeting, held earlier this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze